Placebo for pembrolizumab, KEYTRUDA 25 mg/mL concentrate for solution for infusion, CAPECITABINE , FLUOROURACIL , OXALIPLATIN , CISPLATIN
MK3475-859
Phase 3 small_molecule active
Quick answer
Placebo for pembrolizumab, KEYTRUDA 25 mg/mL concentrate for solution for infusion, CAPECITABINE , FLUOROURACIL , OXALIPLATIN , CISPLATIN for Gastric and gastric esophageal junction (GEJ) adenocarcinoma is a Phase 3 program (small_molecule) at Merck Sharp and Dohme with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Merck Sharp and Dohme
- Indication
- Gastric and gastric esophageal junction (GEJ) adenocarcinoma
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- active